Abu dhabi: Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Board of Directors of the Emirates Drug Establishment, today witnessed the signing of a memorandum of understanding (MoU) between the Emirates Drug Establishment and Mubadala Bio Limited. The agreement was finalized on the sidelines of the World Health Expo (WHX) 2026 and was signed by Dr. Fatima Al Kaabi, Director General of the Emirates Drug Establishment, and Dr. Essam Mohamed, Group Chief Executive Officer of Mubadala Bio Limited.
According to Emirates News Agency, the MoU aims to enhance the UAE's medical products manufacturing sector, supporting national efforts to bolster pharmaceutical security and localize vital drug industries. The agreement focuses on expanding cooperation in building national capacities, sharing knowledge and technology, and supporting research, development, and innovation in the pharmaceutical sector. Additionally, it seeks to attract high-value investments and strengthen the UAE's strategic reserves of medicines.
The partnership is expected to significantly contribute to national priorities by developing a sustainable pharmaceutical manufacturing ecosystem, strengthening the UAE's healthcare sector, and reinforcing its position as a regional and global hub for medical product regulation and production.